Polartechnics raises $11.25m; plans global push
24 November, 2003 by Melissa TrudingerSydney-based medical device firm Polartechnics (ASX:PLT) has used a combination of a share placement and a share purchase plan to raise AUD$11.25 million to expand its global sales and marketing efforts and refine its production processes.
Solbec gets nod on cancer drug trial
24 November, 2003 by Melissa TrudingerPerth biotech Solbec Pharmaceuticals (ASX:SBP) has received approval to commence a Phase I clinical trial on its lead cancer therapeutic SBP002.
Vics pledge $1.5m to wallaby genome project
24 November, 2003 by Melissa TrudingerVictoria's state government has pledged AUD$1.5 million funding for a wallaby genome project, which needs around $6 million to match US National Institutes of Health funding to proceed.
Amrad boosted by US$3 million milestone payment
20 November, 2003 by Melissa TrudingerAmrad (ASX: AML) has received its first milestone payment from its exclusive licensing and research collaboration agreement with Merck, Sharp and Dohme (MSD).
AGT deal targets OTC obesity products
20 November, 2003 by Melissa TrudingerAGT Biosciences (ASX: AGT) has signed an agreement with US drug discovery company the Institutes for Pharmaceutical Discovery (IPD) to collaborate on the development of over-the-counter (OTC) drugs for obesity.
Norwood Releases Data on Immune-boosting Therapy
19 November, 2003 by Graeme O'NeillResearchers working with Melbourne medical technology company Norwood Abbey (ASX: NAL) will present results from their trials on the company's promising immune-boosting therapy in leukaemia and lymphoma patients at next month's meeting of the American Society of Haematology (ASH) in Washington, DC.
Novogen granted key phenoxodiol patent in US
19 November, 2003 by Graeme O'NeillSydney pharmaceutical company Novogen (ASX: NRT, NASDAQ: NVGN) has been granted a US patent covering all applications of its promising anti-cancer therapeutic phenoxodiol for benign and malignant cancers, including ovarian, breast, prostate and cervical cancers.
Agenix's D-dimer diagnostics get boost from international studies
19 November, 2003 by Graeme O'NeillTwo studies published recently in leading medical research journals have given ticks to the SimpliRED and Simplify blood-clot diagnostics developed by Brisbane biotech Agenix (ASX: AGX, NASDAQ: AGXLY)
Brain Resource Company raises $4 million, plans marketing push
19 November, 2003 by Melissa TrudingerSydney-based Brain Resource Company (ASX: BRC) has completed an AUD$4 million placement to institutional investors, giving it the funding to back a marketing push for its brain imaging and functional testing products and services.
Peptech settles Abbott dispute amicably
19 November, 2003 by Melissa TrudingerThe market responded favourably today to news that Peptech has reached an in principle agreement with Abbott to resolve its dispute over royalties for Abbott's anti-TNF alpha arthritis drug HUMIRA.
Genesis Biomedical and ENSI-MED to Merge
18 November, 2003 by Melissa TrudingerGenesis Biomedical (ASX: GBL) has signed a Heads of Agreement with ENSI-MED Manufacturing to acquire 100 per cent of the issued capital of the Canberra-based retractable syringe manufacturer.
GTG tightens patent grip
18 November, 2003 by Graeme O'NeillMelbourne company Genetic Technologies Ltd (ASX: GTG) has settled two of three lawsuits brought against US biotechnology companies for alleged infringements of its non-coding DNA gene-testing patents.
GM surgery to detoxify feed crop
17 November, 2003 by Graeme O'NeillMolecular geneticists at Melbourne University's Institute of Land and Food Resources plan to use RNA interference gene silencing to remove a potent neurotoxin from the manure and feed crop, vetch (Vicia sativa).
CEO change off the agenda at Ventracor AGM
14 November, 2003 by Andrew BirminghamShareholders at Ventracor's annual general meeting in Brisbane yesterday raised not a jot of concern about the board's surprise decision this week to replace CEO Michael Spooner with former Sirtex chief Colin Sutton.
Ex-Novartis CEO joins Pharmaxis
14 November, 2003 by Melissa TrudingerNewly-listed company Pharmaxis (ASX:PXS) has appointed ex-Novartis Australia CEO Gary Phillips as commercial director to look after sales and marketing efforts as the company prepares to complete clinical trials and roll out its first product.
